These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25282505)

  • 21. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
    Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
    Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help.
    Khan AQ; Lees A; Snapper CM
    J Immunol; 2004 Jan; 172(1):532-9. PubMed ID: 14688364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Streptococcus pneumoniae Type 2 Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive Pneumococcal Disease.
    Emmadi M; Khan N; Lykke L; Reppe K; G Parameswarappa S; Lisboa MP; Wienhold SM; Witzenrath M; Pereira CL; Seeberger PH
    J Am Chem Soc; 2017 Oct; 139(41):14783-14791. PubMed ID: 28945368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review: current and new generation pneumococcal vaccines.
    Feldman C; Anderson R
    J Infect; 2014 Oct; 69(4):309-25. PubMed ID: 24968238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism of splenic invariant NKT cell activation dictates localization in vivo.
    King IL; Amiel E; Tighe M; Mohrs K; Veerapen N; Besra G; Mohrs M; Leadbetter EA
    J Immunol; 2013 Jul; 191(2):572-82. PubMed ID: 23785119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in Homing Potentials of Streptococcus pneumoniae-Specific Plasmablasts in Pneumococcal Pneumonia and After Pneumococcal Polysaccharide and Pneumococcal Conjugate Vaccinations.
    Palkola NV; Pakkanen SH; Kantele JM; Pakarinen L; Puohiniemi R; Kantele A
    J Infect Dis; 2015 Oct; 212(8):1279-87. PubMed ID: 25838267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T cells control the generation of nanomolar-affinity anti-glycan antibodies.
    Polonskaya Z; Deng S; Sarkar A; Kain L; Comellas-Aragones M; McKay CS; Kaczanowska K; Holt M; McBride R; Palomo V; Self KM; Taylor S; Irimia A; Mehta SR; Dan JM; Brigger M; Crotty S; Schoenberger SP; Paulson JC; Wilson IA; Savage PB; Finn MG; Teyton L
    J Clin Invest; 2017 Apr; 127(4):1491-1504. PubMed ID: 28287405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mrp1 is involved in lipid presentation and iNKT cell activation by Streptococcus pneumoniae.
    Chandra S; Gray J; Kiosses WB; Khurana A; Hitomi K; Crosby CM; Chawla A; Fu Z; Zhao M; Veerapen N; Richardson SK; Porcelli SA; Besra G; Howell AR; Sharma S; Peters B; Kronenberg M
    Nat Commun; 2018 Oct; 9(1):4279. PubMed ID: 30323255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae.
    Cui Y; Zhang X; Gong Y; Niu S; Yin N; Yao R; Xu W; Li D; Wang H; He Y; Cao J; Yin Y
    Vaccine; 2011 Feb; 29(9):1736-44. PubMed ID: 21238570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
    Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
    Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine.
    Babb R; Chen A; Ogunniyi AD; Hirst TR; Kara EE; McColl SR; Alsharifi M; Paton JC
    Clin Sci (Lond); 2017 Jan; 131(2):169-180. PubMed ID: 27885052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal vaccination with γ-irradiated Streptococcus pneumoniae whole-cell vaccine provides serotype-independent protection mediated by B-cells and innate IL-17 responses.
    Babb R; Chen A; Hirst TR; Kara EE; McColl SR; Ogunniyi AD; Paton JC; Alsharifi M
    Clin Sci (Lond); 2016 May; 130(9):697-710. PubMed ID: 26831937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of T cell independent and cross-reactive antigen on the immune response to pneumococcal conjugate vaccination.
    Rabquer B; Smithson SL; Shriner A; Julie Westerink MA
    Immunol Lett; 2006 Aug; 106(2):187-90. PubMed ID: 16781780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.
    Tian H; Groner A; Boes M; Pirofski LA
    Infect Immun; 2007 Apr; 75(4):1643-50. PubMed ID: 17220309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge.
    Gianfaldoni C; Censini S; Hilleringmann M; Moschioni M; Facciotti C; Pansegrau W; Masignani V; Covacci A; Rappuoli R; Barocchi MA; Ruggiero P
    Infect Immun; 2007 Feb; 75(2):1059-62. PubMed ID: 17145945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.
    Kataoka K; Fujihashi K; Oma K; Fukuyama Y; Hollingshead SK; Sekine S; Kawabata S; Ito HO; Briles DE; Oishi K
    Infect Immun; 2011 Jul; 79(7):2819-28. PubMed ID: 21536790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.
    Wang S; Li Y; Shi H; Scarpellini G; Torres-Escobar A; Roland KL; Curtiss R
    Infect Immun; 2010 Jul; 78(7):3258-71. PubMed ID: 20479086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
    Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.